- Conditions
- Advanced Solid Tumor, Soft Tissue Sarcoma Adult
- Interventions
- SON-1010
- Biological
- Lead sponsor
- Sonnet BioTherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Santa Monica, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 168
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
- Interventions
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
- Drug · Device
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
- Biological · Device
- Lead sponsor
- OncoSec Medical Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- San Francisco, California • Chicago, Illinois
- Conditions
- Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
- Interventions
- Recombinant Interleukin-12
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer, Kidney Cancer
- Interventions
- recombinant interferon alfa, sargramostim, therapeutic autologous lymphocytes, fluorouracil
- Biological · Drug
- Lead sponsor
- St. Luke's Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Small Bowel Cancers, Colorectal Cancers
- Interventions
- CV301, MSB0011359C, N-803, NHS-IL12
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumors
- Interventions
- Production of Genetically-modified T cells, Cyclophosphamide, IP Catheter Insertion, Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells, Fludarabine
- Procedure · Drug · Device + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- AIDS Related Lymphoma, AIDS-Associated Lymphoma
- Interventions
- Filgrastim, Rituximab, EPOCH
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Crohn's Disease
- Interventions
- STA-5326
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- PENNVAX-B, IL-12 DNA plasmids
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- Rochester, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Ovarian Cancer
- Interventions
- Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
- Drug · Biological · Procedure
- Lead sponsor
- Kalinski, Pawel, MD, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Melanoma
- Interventions
- MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine
- Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV-1-infection
- Interventions
- PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
- Biological · Device
- Lead sponsor
- Steven Deeks
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California • San Francisco, California
- Conditions
- Melanoma (Skin)
- Interventions
- MART-1 antigen, recombinant MAGE-3.1 antigen, recombinant interleukin-12
- Biological
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cervical Cancer
- Interventions
- recombinant interleukin-12
- Biological
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 9
- States / cities
- Boston, Massachusetts • Flemington, New Jersey • Hackensack, New Jersey + 6 more
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy
- Biological · Drug · Procedure
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Metastatic Cancer
- Interventions
- interleukin-12 gene
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Common Variable Immunodeficiency
- Interventions
- STA-5326
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- IMNN-001, Carboplatin, Paclitaxel
- Biological · Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Newport Beach, California + 17 more
- Conditions
- Crohn Disease
- Interventions
- JNJ-64304500, Placebo, Adalimumab, Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
- Interventions
- M032 (NSC 733972)
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cryptosporidiosis, HIV Infections
- Interventions
- Interleukin-12, Paromomycin sulfate, Azithromycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, Pegylated Liposomal Doxorubicin Hydrochloride
- Other · Biological · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Orange, California • St Louis, Missouri + 4 more
- Conditions
- ER-Negative PR-Negative HER2-Negative Breast Cancer
- Interventions
- IT-pIL12-EP
- Biological
- Lead sponsor
- OncoSec Medical Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California